AstraZeneca trial flop raises bigger question: Is its pipeline premium becoming more vulnerable? Shares down 6% worst day in 2 years. #AZN
#Biotech
$AZN (+0,22 %)
5D·
AstraZeneca’s trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
2